Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CCL2 | P13500 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861232 | 1.00 | BACE1 (0.41) | BACE1ACMSDBRD4CCL2KDM4E | |
| SCHEMBL2598851 | 1.00 | BACE1 (0.41) | BACE1ACMSDBRD4CCL2KDM4E | |
| SCHEMBL2598850 | 1.00 | BACE1 (0.41) | BACE1ACMSDBRD4CCL2KDM4E | |
| SCHEMBL860481 | 0.85 | BACE1 (0.43) | BACE1ACMSDBRD4CCL2KDM4E | |
| SCHEMBL860482 | 0.85 | BACE1 (0.43) | BACE1ACMSDBRD4CCL2KDM4E | |
| SCHEMBL1805583 | 0.82 | ACMSD (0.39) | BACE1ACMSDSLC5A1HCRTR1HCRTR2 | |
| SCHEMBL2598841 | 0.82 | ACMSD (0.39) | BACE1ACMSDSLC5A1HCRTR1HCRTR2 | |
| SCHEMBL2598843 | 0.82 | ACMSD (0.39) | BACE1ACMSDSLC5A1HCRTR1HCRTR2 | |
| SCHEMBL1805585 | 0.82 | ACMSD (0.39) | BACE1ACMSDSLC5A1HCRTR1HCRTR2 | |
| SCHEMBL1804449 | 0.81 | CHEK1 (0.43) | LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-12-06 | — | — | US | claimed |
| US-20160096851-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2016-04-07 | — | — | US | claimed |
| US-9187483-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2015-11-17 | — | — | US | claimed |
| EP-2432783-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2013-05-01 | — | — | EP | claimed |
| EP-2432783-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2012-03-28 | — | — | EP | claimed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| WO-2010135560-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | WO | claimed |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | claimed |
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-12-06 | — | — | US | disclosed |
| US-9879033-B2 | Modulators of 5-HT receptors and methods of use thereof | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-30 | — | — | US | disclosed |
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20160096851-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2016-04-07 | — | — | US | disclosed |
| US-9187483-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2641907-B1 | Preparation of modulators of 5-HT receptors | ABBVIE INC (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-2571353-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2432783-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011146089-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2010135560-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096851-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | BACE1 3831/4885ACMSD 1601/4885BRD4 2085/4885 |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | BACE1 3831/4885ACMSD 1601/4885BRD4 2085/4885 |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | BACE1 3831/4885ACMSD 1601/4885BRD4 2085/4885 |
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | BACE1 3831/4885ACMSD 1601/4885BRD4 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.